These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9649482)

  • 1. Selective COX-2 inhibitors: are they safe for the stomach?
    Yeomans ND; Cook GA; Giraud AS
    Gastroenterology; 1998 Jul; 115(1):227-9. PubMed ID: 9649482
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pathogenesis of NSAID-induced gastric mucosal damage--search for primary events and role of COX inhibition].
    Takeuchi K; Tanaka A; Miyazawa T
    Nihon Shokakibyo Gakkai Zasshi; 2002 Jul; 99(7):751-9. PubMed ID: 12170703
    [No Abstract]   [Full Text] [Related]  

  • 3. Selective cyclooxygenase-2 inhibitors as potential therapeutic agents for inflammatory diseases.
    Chan CC; Rodger IW
    Adv Exp Med Biol; 1997; 407():157-61. PubMed ID: 9321947
    [No Abstract]   [Full Text] [Related]  

  • 4. [NSAIDs caused gastric mucosal injury: with a special reference to COX-2].
    Sakamoto C
    J Nippon Med Sch; 2003 Feb; 70(1):5-11. PubMed ID: 12646969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity.
    Wallace JL; Bak A; McKnight W; Asfaha S; Sharkey KA; MacNaughton WK
    Gastroenterology; 1998 Jul; 115(1):101-9. PubMed ID: 9649464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [COX-2 expression in gastric cancers].
    Sakamoto C
    Nihon Rinsho; 2001 Apr; 59 Suppl 4():598-603. PubMed ID: 11424449
    [No Abstract]   [Full Text] [Related]  

  • 7. The future of NSAID therapy: selective COX-2 inhibitors.
    Vane JR; Botting RM
    Int J Clin Pract; 2000; 54(1):7-9. PubMed ID: 10750251
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of prostaglandin H synthase 2 deficient mice and implications for mechanisms of NSAID action.
    Morham SG; Langenbach R; Mahler J; Smithies O
    Adv Exp Med Biol; 1997; 407():131-8. PubMed ID: 9321943
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors.
    Szczeklik A; Sanak M
    Clin Exp Allergy; 2002 Mar; 32(3):339-42. PubMed ID: 11940059
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacology and clinical action of COX-2 selective NSAIDs.
    Bovill JG
    Adv Exp Med Biol; 2003; 523():201-14. PubMed ID: 15088852
    [No Abstract]   [Full Text] [Related]  

  • 11. The discovery and function of COX-2.
    Needleman P; Isakson PC
    J Rheumatol Suppl; 1997 Jul; 49():6-8. PubMed ID: 9249644
    [No Abstract]   [Full Text] [Related]  

  • 12. Introduction: mechanism of action of NSAIDs.
    Vane JR
    Br J Rheumatol; 1996 Apr; 35 Suppl 1():1-3. PubMed ID: 8630629
    [No Abstract]   [Full Text] [Related]  

  • 13. COX-2-Selective NSAIDs: new and improved?
    Lichtenstein DR; Wolfe MM
    JAMA; 2000 Sep; 284(10):1297-9. PubMed ID: 10980759
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
    Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
    J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prime suspect.
    Manuel J
    Environ Health Perspect; 1997 Jan; 105(1):28-9. PubMed ID: 9074875
    [No Abstract]   [Full Text] [Related]  

  • 16. The promise of coxibs: how far have we progressed?
    Schumacher HR
    J Pain Symptom Manage; 2002 Apr; 23(4 Suppl):S1-4. PubMed ID: 11992742
    [No Abstract]   [Full Text] [Related]  

  • 17. COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease.
    Crofford LJ
    Arthritis Res Ther; 2003; 5(1):25-7. PubMed ID: 12716444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
    Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
    J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2 inhibitors: background knowledge for clinical use. Summary.
    Katori M
    Inflamm Res; 1998 Oct; 47 Suppl 2():S117. PubMed ID: 9831334
    [No Abstract]   [Full Text] [Related]  

  • 20. [Significance of COX-2].
    Tatsuguchi A; Sakamoto C
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():207-10. PubMed ID: 11979779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.